Grammer L C, Shaughnessey M A, Shaughnessy J J, Patterson R
J Allergy Clin Immunol. 1984 May;73(5 Pt 1):557-60. doi: 10.1016/0091-6749(84)90510-4.
Fifty patients recruited with ragweed allergic rhinitis were studied. Twenty-three of these patients had asthma. On the basis of cutaneous end point titration to ragweed, patients were randomly assigned to polymerized ragweed (PRW), placebo, or untreated groups. PRW patients received the equivalent of 1200 micrograms AgE in 15 weekly injections. All patients were followed through the ragweed season with daily rhinitis symptom-medication diaries. All patients had determinations of IgE against AgE and total (blocking) antibody to AgE before and after the injection series. In these patients selected for allergic rhinitis, the presence or absence of asthma did not significantly influence rhinitis symptom-medication scores or the values of immunologic parameters. Moreover, whether or not patients had asthma, those who received PRW had an increase in total AgE binding with no increase in IgE-a-AgE and significantly lower rhinitis scores than those who did not.
对50名患有豚草过敏性鼻炎的患者进行了研究。其中23名患者患有哮喘。根据对豚草的皮肤终点滴定,患者被随机分配到聚合豚草(PRW)组、安慰剂组或未治疗组。PRW组患者在15次每周注射中接受相当于1200微克变应原提取物(AgE)的剂量。在豚草季节期间,通过每日鼻炎症状-用药日记对所有患者进行随访。在注射系列前后,对所有患者测定针对AgE的IgE以及针对AgE的总(阻断)抗体。在这些被选来研究过敏性鼻炎的患者中,哮喘的有无并未显著影响鼻炎症状-用药评分或免疫参数值。此外,无论患者是否患有哮喘,接受PRW治疗的患者与未接受治疗的患者相比,总AgE结合增加,IgE-a-AgE未增加,且鼻炎评分显著更低。